"New Jersey Hematology Oncology Associates (NJHOA) was founded in Brick, NJ by Dr. Amin in 1996. As our practice grew there was a need for another associate, Dr. Pavlak-Schenk joined the practice in 2000. NJHOA expanded its practice to Southern Ocean County and in 2005 they opened an additional office in Toms River, NJ. Dr. Agrawal joined NJHOA in 2011. Currently, all of our physicians have admitting and consulting privileges at: Ocean Medical Center, Jersey Shore University Medical Center, Community Medical Center, and Kimball Medical Center."

During the past decade, New Jersey Hematology & Oncology Associates conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 6 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 6 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New Jersey Hematology & Oncology Associates" #1 sponsor was "Incyte Corporation" with 3 trials, followed by "BeiGene" with 1 trials sponsored, "Bio-Path Holdings, Inc." with 1 trials sponsored, "Calithera Biosciences, Inc" with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New Jersey Hematology & Oncology Associates" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "New Jersey Hematology & Oncology Associates" are "Myelofibrosis" (3 trials), "Breast Cancer" (2 trials), "Post Essential Thrombocythemia Myelofibrosis" (2 trials), "Post Polycythemia Vera Myelofibrosis" (2 trials) and "Primary Myelofibrosis" (2 trials). Many other conditions were trialed in "New Jersey Hematology & Oncology Associates" in a lesser frequency.

Most popular intervention types in "New Jersey Hematology & Oncology Associates" are "Drug" (16 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Azacitidine" (2 trials), "Placebo" (2 trials), "parsaclisib" (2 trials) and "placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "New Jersey Hematology & Oncology Associates" are 15 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "New Jersey Hematology & Oncology Associates". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in New Jersey Hematology & Oncology Associates, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in New Jersey Hematology & Oncology Associates, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

New Jersey Hematology & Oncology Associates has several departments that took part in Clinical trials: "New Jersey Center for Cancer Research" - 8 trials